Solid Biosciences (SLDB) Current Deferred Revenue (2020 - 2022)

Solid Biosciences has reported Current Deferred Revenue for 3 years, with the latest figure at $6.2 million in Q1 2022.

• Quarterly Current Deferred Revenue fell 65.07% year-over-year to $6.2 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $6.2 million (down 65.07% YoY) and the FY2021 annual result came in at $8.1 million, down 61.0% from the prior year.
• Current Deferred Revenue retreated to $6.2 million in Q1 2022 per SLDB's latest filing, from $8.1 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $20.7 million in Q4 2020 and troughed at $6.2 million in Q1 2022.
• A 3-year average of $12.6 million and a median of $11.6 million in 2021 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue sank 61.0% in 2021, then plunged 65.07% in 2022.
• Over 3 years, Current Deferred Revenue stood at $20.7 million in 2020, then tumbled by 61.0% to $8.1 million in 2021, then slipped by 23.64% to $6.2 million in 2022.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $6.2 million, $8.1 million, and $8.9 million for Q1 2022, Q4 2021, and Q3 2021 respectively.